Connect Biopharma Holdings Limited Forecasted to Post FY2022 Earnings of ($2.11) Per Share (NASDAQ:CNTB)

Connect Biopharma Holdings Limited (NASDAQ:CNTBGet Rating) – Stock analysts at Cantor Fitzgerald decreased their FY2022 earnings per share (EPS) estimates for shares of Connect Biopharma in a note issued to investors on Thursday, September 15th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post earnings per share of ($2.11) for the year, down from their prior forecast of ($2.10). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Connect Biopharma’s current full-year earnings is ($1.89) per share. Cantor Fitzgerald also issued estimates for Connect Biopharma’s FY2023 earnings at ($2.11) EPS.

Connect Biopharma Stock Down 1.4 %

NASDAQ:CNTB opened at $1.44 on Monday. The business’s 50 day moving average is $1.22 and its two-hundred day moving average is $1.65. Connect Biopharma has a 52 week low of $0.56 and a 52 week high of $25.25.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Vident Investment Advisory LLC bought a new stake in shares of Connect Biopharma in the 1st quarter worth approximately $55,000. Ensign Peak Advisors Inc bought a new stake in shares of Connect Biopharma in the 4th quarter worth approximately $131,000. Woodline Partners LP bought a new stake in shares of Connect Biopharma in the 1st quarter worth approximately $132,000. Invesco Ltd. lifted its holdings in shares of Connect Biopharma by 135.9% in the 1st quarter. Invesco Ltd. now owns 60,449 shares of the company’s stock worth $183,000 after purchasing an additional 34,820 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Connect Biopharma by 184.7% in the 2nd quarter. Renaissance Technologies LLC now owns 66,900 shares of the company’s stock worth $58,000 after purchasing an additional 43,400 shares during the last quarter. Institutional investors own 27.19% of the company’s stock.

About Connect Biopharma

(Get Rating)

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.

Further Reading

Earnings History and Estimates for Connect Biopharma (NASDAQ:CNTB)

Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.